Can I Take Ashwagandha With Ozempic?

What Kind of Interaction Is This?

Ashwagandha does not meaningfully alter CYP450 enzymes at typical oral doses, and semaglutide is a peptide cleared by proteolytic degradation rather than hepatic metabolism. That means a classical pharmacokinetic interaction, the type where one drug changes how the other is absorbed, distributed, or eliminated, is unlikely. A 2020 pharmacology review confirmed that Withania somnifera has negligible inhibitory effect on CYP3A4 and CYP2D6 at doses up to 600 mg/day.

The real concern is pharmacodynamic. Both substances act on overlapping biological pathways: cortisol regulation, insulin sensitivity, and thyroid hormone levels. When two agents push the same pathway in the same direction, effects can add up in ways that are not always predictable.

Why Pharmacodynamics Matter More Than Metabolism

Semaglutide works by binding GLP-1 receptors in the pancreas, gut, and brain. It increases glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying. The FDA label for Ozempic (NDA 209637) documents mean HbA1c reductions of 1.5% at 0.5 mg and 1.8% at 1.0 mg over 30 weeks.

Ashwagandha influences the hypothalamic-pituitary-adrenal axis, insulin receptor signaling, and thyroid hormone synthesis. Understanding each pathway separately makes the combination easier to evaluate.

Blood Glucose and Hypoglycemia Risk

Semaglutide lowers blood glucose in a glucose-dependent manner. On its own, it carries a low hypoglycemia risk. Ashwagandha adds a modest but real glucose-lowering signal.

Ashwagandha's Glucose-Lowering Evidence

A 2015 randomized controlled trial (N=25) published in the Journal of the International Society of Sports Nutrition found that 300 mg twice-daily ashwagandha root extract reduced fasting blood glucose by roughly 13.6 mg/dL versus placebo over 8 weeks. That study is indexed at PubMed PMID 26609282.

A separate 2019 RCT (N=60) in adults with type 2 diabetes tested 250 mg ashwagandha root extract twice daily alongside standard antidiabetic therapy. Fasting glucose fell an additional 9.8 mg/dL in the ashwagandha group compared with the control arm. Full text is available at PMID 30928564.

What This Means Alongside Ozempic

Semaglutide alone rarely causes hypoglycemia below 70 mg/dL. Adding ashwagandha's 10 to 14 mg/dL glucose-lowering effect is unlikely to tip most patients into a dangerous range unless they are also taking insulin or a sulfonylurea. Patients on triple therapy (semaglutide plus sulfonylurea plus ashwagandha) should discuss a sulfonylurea dose reduction with their prescriber. The ADA Standards of Medical Care in Diabetes 2024 recommend reducing or discontinuing sulfonylureas when adding any agent with additive hypoglycemic potential.

Self-monitoring of blood glucose at 2-hour post-meal and fasting timepoints for the first 4 weeks after starting ashwagandha is a sensible precaution.

Cortisol Modulation and Its Downstream Effects

Ashwagandha is classified as an adaptogen. Its most consistent clinical effect is cortisol reduction.

Clinical Evidence on Cortisol

A double-blind RCT (N=64) published in Medicine (2019) found that 240 mg/day standardized ashwagandha extract reduced serum cortisol by 22.2% versus 4.4% in the placebo group over 60 days. PMID 31517876.

A larger trial (N=98) testing 300 mg twice daily for 8 weeks reported a 27.9% reduction in morning serum cortisol. PMID 23439798.

How Cortisol Connects to Semaglutide's Goals

Chronic cortisol elevation worsens insulin resistance. Reducing cortisol may improve hepatic glucose output and peripheral insulin sensitivity. In that sense, ashwagandha's cortisol effect could support the same metabolic goals semaglutide targets. The concern cuts the other way too: if cortisol falls sharply in a patient whose blood pressure or inflammatory tone depends on moderate cortisol levels, fatigue, dizziness, or hypotension may appear. These are not life-threatening in otherwise healthy adults, but they can be disorienting.

Patients starting ashwagandha while on semaglutide should note any new-onset lightheadedness within the first 2 weeks and report it promptly.

Thyroid Hormone Effects: the Most Carefully Watched Signal

This is the intersection that requires the most clinical attention.

Ashwagandha and Thyroid Hormones

A 2017 RCT (N=50) in adults with subclinical hypothyroidism tested 600 mg/day ashwagandha root extract over 8 weeks. Serum T3 rose by 41.5% and serum T4 rose by 19.6% compared with placebo. TSH fell significantly. PMID 28829155.

A second trial in healthy adults taking 600 mg/day for 8 weeks also showed increases in T3 and T4. PMID 30531457.

Ozempic's Thyroid Warning

The FDA-approved Ozempic prescribing information carries a black-box warning about thyroid C-cell tumors observed in rodent studies. The label states: "Ozempic causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice."

The label specifically contraindicates use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Why Combining Both Matters for Thyroid Monitoring

Ashwagandha raises circulating thyroid hormones. Semaglutide carries unresolved questions about thyroid C-cell biology in humans. No published trial has examined their combined thyroid effect. Patients with known thyroid disease, those already on levothyroxine, and anyone with a family history that includes MTC should get baseline TSH and free T4 before starting ashwagandha and recheck at 8 to 12 weeks. The American Thyroid Association recommends TSH monitoring every 6 to 12 months in patients on stable thyroid-active medications, and more frequently when new interacting agents are introduced.

Patients without known thyroid disease and no relevant family history face a much lower level of concern, but a single baseline TSH is still worth ordering.

Testosterone and Androgen Considerations

Some patients take ashwagandha for its modest testosterone-supporting effects. This is worth discussing in the context of metabolic therapy.

What the Evidence Shows

A 16-week RCT (N=57) in resistance-trained men found that 300 mg twice-daily ashwagandha root extract increased serum testosterone by 96.2 ng/dL versus 18 ng/dL in the placebo group. PMID 26609282.

Higher testosterone correlates with improved insulin sensitivity in men with type 2 diabetes, an effect that runs in the same direction as semaglutide's glucose-lowering action. A 2016 meta-analysis in the European Journal of Endocrinology (N=1,954 across 7 RCTs) found that testosterone replacement reduced HbA1c by 0.87% on average in hypogonadal men with type 2 diabetes.

No interaction concern between ashwagandha's testosterone effect and semaglutide's GLP-1 mechanism has been identified. This combination appears neutral at worst and possibly synergistic in the metabolic direction, though head-to-head data are absent.

GLP-1 Receptor Biology and Any Direct Ashwagandha Overlap

A reasonable question is whether ashwagandha affects GLP-1 secretion or receptor expression directly, which would create a direct mechanistic overlap with semaglutide.

Preclinical Signals

In vitro and animal data suggest that withanolides (the active glycosides in ashwagandha) may have mild insulinotropic effects via pancreatic beta-cell protection, possibly through reduced oxidative stress rather than GLP-1 receptor activation. A 2020 study in Phytomedicine reported withanolide-A-induced protection of MIN6 pancreatic beta cells against streptozotocin-induced apoptosis (PMID 32035388).

No human trial has measured ashwagandha's effect on endogenous GLP-1 levels. The existing signal is preclinical only and should not be used to justify dosing decisions.

Gastric Emptying: a Potential Interaction Point

Semaglutide slows gastric emptying, which affects the absorption rate of orally administered compounds, including supplements taken by mouth. The SUSTAIN-1 trial (N=388) documented a 13% reduction in 5-hour gastric emptying rate with semaglutide 0.5 mg.

Ashwagandha is absorbed in the small intestine. Delayed gastric emptying may slow its absorption slightly, potentially flattening peak plasma concentrations of withanolides. This is not dangerous, but it means the supplement's onset of cortisol-lowering effects could be slower than in someone not on a GLP-1 agent. Taking ashwagandha at least 30 minutes before a meal may help offset some of this delay, though no specific data support a precise timing window.

A Practical Decision Framework for Patients and Prescribers

Use this four-step process before combining ashwagandha with semaglutide.

Step 1. Screen for Contraindications First

Rule out personal or family history of MTC or MEN2. These patients should not start ashwagandha without explicit oncology or endocrinology clearance given the unresolved thyroid C-cell question from the semaglutide label.

Step 2. Get a Baseline Lab Panel

Order fasting glucose, HbA1c, TSH, free T4, and a complete metabolic panel before ashwagandha is added. This creates a reference point for any changes at follow-up. The Endocrine Society's 2021 clinical practice guideline on diabetes pharmacotherapy recommends baseline metabolic panels before adding any new agent to an existing regimen.

Step 3. Start Low, Watch Glucose

Begin with 300 mg/day ashwagandha root extract (standardized to at least 5% withanolides) rather than jumping to 600 mg. Check fasting glucose at 2 weeks. If glucose is stable and no dizziness is present, the patient may increase to 600 mg/day with prescriber approval.

Step 4. Recheck Labs at 8 to 12 Weeks

Repeat TSH, free T4, fasting glucose, and HbA1c. If TSH has dropped below 0.5 mIU/L or free T4 has risen above the normal range, hold ashwagandha and refer to endocrinology. An HbA1c drop of more than 0.5% beyond semaglutide's expected effect warrants review of any concurrent sulfonylurea dose.

Safety Profile of Ashwagandha Alone

Before combining with any prescription drug, understanding ashwagandha's standalone safety record provides useful context.

Common Adverse Effects

At 300 to 600 mg/day, the most commonly reported adverse effects in RCTs are GI upset (nausea, loose stools) in roughly 10 to 15% of participants, drowsiness, and headache. A 2021 systematic review (N=1,000 across 12 RCTs) published in Nutrients found no serious adverse events attributable to ashwagandha at doses up to 1,000 mg/day for up to 12 weeks.

GI upset overlaps with semaglutide's own profile of nausea (up to 20% incidence in SUSTAIN trials). The SUSTAIN-7 trial (N=1,201) reported nausea in 21% of participants on semaglutide 1.0 mg. Patients starting both simultaneously may have difficulty distinguishing the source of GI symptoms. Stagger introduction by 4 to 6 weeks when possible.

Rare but Reported Concerns

Case reports have linked high-dose ashwagandha (above 1,000 mg/day) to hepatotoxicity, with at least six cases documented in the literature as of 2023. A 2023 case series in Liver International (PMID 37157154) identified ashwagandha as the probable causative agent in four patients with drug-induced liver injury. Standard doses of 300 to 600 mg/day do not carry this documented risk, but liver function tests (ALT, AST) are worth adding to the baseline panel for patients taking higher doses.

What Mainstream Drug Interaction Databases Say

The Natural Medicines Database (formerly Natural Standard) rates the ashwagandha and antidiabetic drug combination as a "moderate" interaction, based on the additive glucose-lowering signal, with a recommendation to monitor blood glucose more frequently. No specific semaglutide entry exists in the database because semaglutide postdates most of the foundational ashwagandha interaction research. The NIH Office of Dietary Supplements Botanical Interaction Fact Sheet confirms that Withania somnifera may enhance the effects of thyroid medications and immunosuppressants, with glucose-lowering agents listed as warranting clinical attention.

No case reports of a clinically harmful ashwagandha-semaglutide interaction have been published in PubMed-indexed journals as of July 2025.

A Note on Quality of Evidence

The evidence base here is built from separate mechanistic trials, not a study of the combination itself. That gap matters. The glucose and cortisol interaction inferences are reasonable extrapolations from well-replicated single-agent RCTs. The thyroid interaction inference carries more uncertainty because the semaglutide thyroid C-cell signal comes from rodent data, not human oncology surveillance. The FDA's 2023 postmarketing commitment tracking for semaglutide products (available at fda.gov) lists ongoing thyroid tumor surveillance as an open commitment with no human signal detected as of the most recent update.

The absence of a detected human signal does not mean the risk is zero. It means the current evidence is insufficient to quantify it.